Program
LT-002-158
A development code. Also written as “LT-002-158 tablets” and “LT-002-158 Tablets”.
Its studies are mostly in Dermatitis, Atopic · Hidradenitis Suppurativa, led by Leadingtac Pharmaceutical (Shaoxing).
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Leadingtac Pharmaceutical (Shaoxing) | 33 open or running | phase 2since Apr 2, 2025 | Apr 2, 2025 | Jan 2028phase 2 · NCT07895615 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 2, 2025First studies: 2 phase 2 studiesFirst studyNCT06932003, NCT06931990
- Oct 19, 2026Phase 2 study in Dermatitis, AtopicNCT07895615 · 160 planned · China
Ahead
- Jan 2028Primary completion: phase 2 study in Dermatitis, AtopicNCT07895615
- Feb 17, 2028Primary completion: phase 2 study in Dermatitis, AtopicNCT06931990
- Oct 30, 2028Primary completion: phase 2 study in Hidradenitis SuppurativaNCT06932003
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07895615Dermatitis, Atopic · China | 2 | Recruiting | Jan 2028 | 160 |
| NCT06932003Hidradenitis Suppurativa · China | 2 | Recruiting | Oct 30, 2028 | 12 |
| NCT06931990Dermatitis, Atopic · China | 2 | Recruiting | Feb 17, 2028 | 24 |
How it is read
Names in the registry
- “LT-002-158”, 1 entry
- “LT-002-158 tablets”, 1 entry
- “LT-002-158 Tablets”, 1 entry
Codes read as this program: LT002158.
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 2 studies
- Hidradenitis Suppurativa, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.